1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Alstrom Syndrome: new trials by email Literature Review of Alstrom Syndrome trials Research Report on Alstrom Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity Setmelanotide, Placebo - Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 52 | 2018-11-23 | 2023-12-01 |
Bardet-Biedl Syndrome (1) · Obesity (1)
Abnormalities, Multiple (1) · Body Weight (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Ciliopathies (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Eye Diseases (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Hereditary Sensory and Motor Neuropathy (1) · Heredodegenerative Disorders, Nervous System (1) · Hypothalamic Diseases (1) · Nervous System Diseases (1) · Nervous System Malformations (1)
setmelanotide (1)
Rhythm Pharmaceuticals, Inc. (1)
Canada (1) · France (1) · Puerto Rico (1) · Spain (1) · United Kingdom (1) · United States (1)
David Meeker, MD (1)
PMID 34013094, PMID 36356613, PMID 36647077, PMID 36961653, PMID 41703984, PMID 42821228
2018 (1)